JP2024026104A5 - - Google Patents

Info

Publication number
JP2024026104A5
JP2024026104A5 JP2023195267A JP2023195267A JP2024026104A5 JP 2024026104 A5 JP2024026104 A5 JP 2024026104A5 JP 2023195267 A JP2023195267 A JP 2023195267A JP 2023195267 A JP2023195267 A JP 2023195267A JP 2024026104 A5 JP2024026104 A5 JP 2024026104A5
Authority
JP
Japan
Prior art keywords
neonatal
pharmaceutical composition
pain
convulsions
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023195267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024026104A (ja
Filing date
Publication date
Priority claimed from JP2020551340A external-priority patent/JP7757036B2/ja
Application filed filed Critical
Publication of JP2024026104A publication Critical patent/JP2024026104A/ja
Publication of JP2024026104A5 publication Critical patent/JP2024026104A5/ja
Pending legal-status Critical Current

Links

JP2023195267A 2018-03-19 2023-11-16 Kv7チャネル活性化剤の構成および使用方法 Pending JP2024026104A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862644932P 2018-03-19 2018-03-19
US201862644902P 2018-03-19 2018-03-19
US62/644,932 2018-03-19
US62/644,902 2018-03-19
US201862663438P 2018-04-27 2018-04-27
US62/663,438 2018-04-27
US201862697198P 2018-07-12 2018-07-12
US62/697,198 2018-07-12
JP2020551340A JP7757036B2 (ja) 2018-03-19 2019-03-19 Kv7チャネル活性化剤の構成および使用方法
PCT/US2019/023039 WO2019183148A1 (en) 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020551340A Division JP7757036B2 (ja) 2018-03-19 2019-03-19 Kv7チャネル活性化剤の構成および使用方法

Publications (2)

Publication Number Publication Date
JP2024026104A JP2024026104A (ja) 2024-02-28
JP2024026104A5 true JP2024026104A5 (https=) 2026-01-22

Family

ID=67905138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551340A Active JP7757036B2 (ja) 2018-03-19 2019-03-19 Kv7チャネル活性化剤の構成および使用方法
JP2023195267A Pending JP2024026104A (ja) 2018-03-19 2023-11-16 Kv7チャネル活性化剤の構成および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551340A Active JP7757036B2 (ja) 2018-03-19 2019-03-19 Kv7チャネル活性化剤の構成および使用方法

Country Status (13)

Country Link
US (5) US10851067B2 (https=)
EP (1) EP3768677A4 (https=)
JP (2) JP7757036B2 (https=)
KR (3) KR102731128B1 (https=)
CN (6) CN118955402A (https=)
AU (3) AU2019239955B2 (https=)
BR (1) BR112020018933A2 (https=)
CA (1) CA3093976A1 (https=)
IL (2) IL277419B2 (https=)
MX (2) MX2020009693A (https=)
SG (1) SG11202008030WA (https=)
WO (1) WO2019183148A1 (https=)
ZA (1) ZA202308070B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3572405T1 (sl) * 2014-09-12 2023-12-29 Biohaven Therapeutics Ltd. Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
CN118955402A (zh) * 2018-03-19 2024-11-15 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento
CA3266454A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS
AU2023338196A1 (en) * 2022-09-06 2025-04-10 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators
KR20260049605A (ko) * 2023-08-10 2026-04-14 바이오하벤 테라퓨틱스 리미티드 Kv7.2/7.3 칼륨 채널 활성제의 서방형 제형
IL326832A (en) * 2023-09-15 2026-04-01 Biohaven Therapeutics Ltd Methods for treating epilepsy and related disorders using potent and selective potassium channel activators
WO2025103406A1 (zh) * 2023-11-15 2025-05-22 南京明德新药研发有限公司 6并5杂芳基衍生物及其应用
WO2025137661A1 (en) * 2023-12-22 2025-06-26 Biohaven Therapeutics Ltd. Combination treatment of neurological disorders
US20260049061A1 (en) * 2024-03-18 2026-02-19 HUMANWELL PHARMACEUTICAL US, Inc. Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof
WO2026042005A1 (en) 2024-08-18 2026-02-26 Biohaven Therapeutics Ltd. Prodrugs of benzimidazol-1,2-yl amide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
JPH0772181A (ja) 1993-09-03 1995-03-17 Advantest Corp 電位波形測定方法および装置
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
EP2186804B1 (en) 2007-08-10 2015-06-17 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
TWI482768B (zh) 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
WO2010051819A1 (en) 2008-11-10 2010-05-14 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
US8232273B2 (en) 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
CN103168032A (zh) 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
WO2015023958A1 (en) * 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
SI3572405T1 (sl) 2014-09-12 2023-12-29 Biohaven Therapeutics Ltd. Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
CN118955402A (zh) * 2018-03-19 2024-11-15 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
BR112022004847A2 (pt) * 2019-09-17 2022-06-07 Knopp Biosciences Llc Método para tratar uma doença ou distúrbio de neurodesenvolvimento

Similar Documents

Publication Publication Date Title
JP2024026104A5 (https=)
JP2009509920A5 (https=)
JP2010505794A5 (https=)
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
JP2018104454A5 (https=)
CA2505195A1 (en) Quinazolinones as potassium channel modulators
JP2013519728A5 (https=)
JP2013544277A5 (https=)
JP2010523562A5 (https=)
CN110366555A (zh) 甾族类衍生物调节剂、其制备方法和应用
JP2008044931A5 (https=)
JP2020506899A5 (https=)
JP2008533087A5 (https=)
CA2441565A1 (en) Bisarylamines as potassium channel openers
JP2005521723A5 (https=)
JP2009530302A5 (https=)
RU2015137619A (ru) Замещенные нафтиридиновые и хинолиновые соединения как ингибиторы мао
JP2020524679A5 (https=)
JP2007509043A5 (https=)
JP2012508275A5 (https=)
RU2013142364A (ru) Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а)
JP2022502405A5 (https=)
JP2016506939A5 (https=)
JPWO2019183148A5 (https=)
JP2008543915A5 (https=)